Varenicline
FDA Label NDC 60687-648

49 label sections · Submitted to the FDA by American Health Packaging · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by American Health Packaging for the product Varenicline (NDC 60687-648). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 usual dosage for adults, 2.2 dosage in special populations, 3 dosage forms and strengths, 4 contraindications, 5.1 neuropsychiatric adverse events including suicidality, 5.2 seizures, 5.3 interaction with alcohol, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Packaging Information

American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Par Pharmaceutical as follows:
(1 mg / 30 UD) NDC 60687-648-21 packaged from NDC 49884-156

Distributed By:
American Health Packaging
Columbus, OH 43217

8464821/1223

Package/Label Display Panel – Carton – 1 Mg

NDC 60687- 648-21

Varenicline
Tablets

1 mg

30 Tablets (3 x 10)                 Rx Only

PHARMACIST: Dispense with the accompanying Medication Guide to each patient.

Each Film-Coated Tablet Contains:
1.71 mg varenicline tartrate equivalent to 1 mg varenicline free base.

Usual Dosage: See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted between
15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

The drug product contained in this package is from
NDC # 49884-156, Par Pharmaceutical.

Distributed by:
American Health Packaging
Columbus, Ohio 43217

764821
0464821/1223

Package/Label Display Panel – Blister – 1 Mg

Varenicline
Tablet

1 mg

* Please review the disclaimer below.